William Blair & Company
ONCY

William Blair & Company’s Oncolytics Biotech ONCY Stock Holding History

William Blair & Company’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,467
Closed -$27.5K – 1986
2025
Q4 		$27.5K Buy
+31,467
New +$34K ﹤0.01% 1703

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

William Blair & Company's ONCY Position: Q1 2026 in Review

William Blair & Company sold out of Oncolytics Biotech (ONCY) in Q1 2026, closing a stake of 31,467 shares — an estimated $27.5K sold.

William Blair & Company first reported a position in ONCY in Q4 2025 and held it in 1 quarter. The position peaked at $27.5K in Q4 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • William Blair & Company reported no remaining Oncolytics Biotech position as of Q1 2026 after selling out during the quarter.
  • William Blair & Company sold 31,467 Oncolytics Biotech shares in Q1 2026, an estimated $27.5K.
  • William Blair & Company first reported a position in Oncolytics Biotech in Q4 2025 and held it in 1 quarter.
  • William Blair & Company's Oncolytics Biotech position peaked at $27.5K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.